| 1.68 0.005 (0.3%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.24 |
| Resists | First : | 1.8 | Second : | 1.91 |
| Pivot price | 1.7 |
|||
| Supports | First : | 1.61 | Second : | 1.33 |
| MAs | MA(5) : | 1.7 |
MA(20) : | 1.7  |
| MA(100) : | 2.17 |
MA(250) : | 5.28 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 17.8 |
D(3) : | 25.6 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 10.97 | Low : | 0.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RPHM ] has closed above bottom band by 31.1%. Bollinger Bands are 91.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 75 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.7 - 1.72 | 1.72 - 1.73 |
| Low: | 1.63 - 1.65 | 1.65 - 1.66 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Wed, 24 Apr 2024
BML Capital Management LLC Takes Position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) - MarketBeat
Sat, 20 Apr 2024
Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as ... - Yahoo Canada Shine On
Thu, 18 Apr 2024
Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be ... - Yahoo Canada Shine On
Thu, 28 Mar 2024
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update - GlobeNewswire
Thu, 11 Jan 2024
RPHM Stock Quote Price and Forecast - CNN
Thu, 14 Dec 2023
Healthcare Stocks Making Moves Thursday: STTK, IMMX, CDXS, ESPR, RPHM, APLS, NXTC, MOTS - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 82.1 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,590 (K) |
| EPS | -2.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.8 % |
| Return on Equity (ttm) | -82.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | 0.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|